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And diff’ring judgments serve but to declare, that Truth lies
somewhere, if we knew but where.—William Cowper, Hope
Ever since the advent of percutaneous treatment of coronary
disease, restenosis has been the “Achilles’ heel,” limiting
long-term success. Early clinical studies evaluated numerous
pharmacologic agents that had proved beneﬁcial in animal
models, only to ﬁnd that these agents had no effect on
restenosis in humans. A second group of trials looked at the
effect of newer devices on restenosis, again without apparent
success. However, these two groups of trials did further our
understanding of the biology of arterial injury and spawned a
new generation of pharmaceutical agents and devices for which
there is great hope. Current thinking is that some neointimal
growth will occur in any injured artery, and therefore maximiz-
ing the size of the lumen after the procedure is necessary to
accomodate this growth without development of a ﬂow-
limiting stenosis. Minimal residual stenoses are now routinely
obtained with intracoronary stents, and interest has revived in
directional coronary atherectomy for this reason. However,
restenosis occurs in patients treated with both of these modal-
ities, and we now realize that further improvements in rates of
restenosis will require control of neointimal formation. Eval-
uation of the effects of heparin-coated stents and coronary
irradiation are two modalities now under investigation.
Thrombin inhibition would seem to be a powerful approach
to controlling neointimal formation after vascular injury.
Thrombin is a multifunctional serine proteinase that is con-
centrated at sites of vascular injury. In addition to its well
known hemostatic effects, thrombin activates platelets, stimu-
lates smooth muscle cell growth and serves as a chemotactic
agent for macrophages. These effects are mediated by throm-
bin binding of a seven-transmembrane, glycoprotein coupled
cell surface receptor. Expression of the thrombin receptor is
increased in both atherosclerotic and balloon-injured arteries.
On the basis of these results and promising data from animal
studies (1) showing that thrombin inhibition decreased neoin-
timal formation in injured arteries, the HELVETICA study (2)
was launched to determine the effect of hirudin, a potent,
direct antithrombin, on restenosis after balloon angioplasty.
These investigators recruited 1,141 patients with unstable
angina (deﬁned as new-onset or worsening angina) who were
undergoing angioplasty and randomized them to one of three
treatment groups: heparin bolus plus 1-day infusion; hirudin
bolus plus 1-day infusion; or hirudin bolus plus 1-day infusion
plus subcutaneous hirudin for 2 days. The hirudin dose used
(40-mg bolus plus 0.2-mg/h infusion) was less than that used in
animal studies because higher doses resulted in unacceptable
levels of bleeding complications. Results of this trial showed
that although treatment with hirudin lessened early cardiac
events, there was no effect on angiographic restenosis, as
measured at 6 months, or on event-free survival as measured at
7 months.
Hirudin now joins the long list of agents that have been
shown to limit neointimal growth in animal models of balloon
injury but which fail to lessen restenosis when used in humans.
But before we relegate thrombin inhibition to the restenosis
scrapheap, it is important to keep several issues in mind. As the
HELVETICA investigators note, thrombin inhibition was in-
complete at the doses of hirudin used. Thus, although hirudin
does not reduce restenosis at doses that are safe, it is still
unclear whether inhibition of thrombin-induced events by
another agent may eventually be useful in patients undergoing
angioplasty. Additionally, the lack of a therapeutic effect in
humans does not preclude gaining potential insights into
vascular growth responses from an examination of the effects
of thrombin inhibition after arterial injury in animals.
In this issue of the Journal, Abendschein et al. (3) report
that treatment with hirudin (2-mg/kg body weight bolus fol-
lowed by 2-mg/kg per h infusion for 3 h) reduced histologic
stenosis in carotid arteries of hypercholesterolemic minipigs 4
weeks after balloon dilation. They also found that a 3-h
infusion of recombinant tick anticoagulant peptide (rTAP), a
speciﬁc factor Xa inhibitor, reduced histologic stenosis, al-
though not by the same magnitude observed with hirudin
treatment. These results are in concordance with Ragosta et al.
(4) who found that a 2-h infusion of rTAP lessened histologic
restenosis in the cholesterol-fed rabbit model of focal athero-
sclerosis. As both of these groups note, inhibition of factor Xa
is an attractive therapeutic option because of the central role
that factor Xa plays in catalyzing the formation of thrombin
from prothrombin. Given that thrombin inhibition through
treatment with hirudin or rTAP has now been shown to lessen
intimal growth in two distinct animal models, what further
studies need to be done?
There are four questions that these models are particularly
suited to address at this point. The ﬁrst is the mechanism by
which thrombin stimulates intimal growth after vascular injury.
Ragosta et al. (5) have shown that hirudin does not effect
3H-thymidine incorporation in the vessel wall despite having a
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marked effect on histologic restenosis as measured at 28 days.
Thus, this model provides an opportunity to identify a mech-
anism (e.g., macrophage recruitment, extracellular matrix pro-
duction), independent of proliferation, that plays a role in
intimal growth. Second, it is unclear why a brief infusion has
such a persistent effect on vascular growth. Hirudin was
infused for 2 h in the rabbit or 3 h in the pig, yet intimal growth
was reduced as measured at 28 days. These data suggest that
profound responses are elicited at the time of injury and that
inhibition of these responses can reduce delayed growth re-
sponses. Third, the role that plaque composition plays in the
restenotic process can be addressed utilizing this model. Mul-
tiple mechanisms probably contribute to restenosis, and agents
that are ineffective in large populations may still have a role in
individual patients. One potential hypothesis is that thrombin
inhibition is effective at limiting restenosis after balloon dila-
tion of plaques in which tissue factor expression is elevated.
Vascular tissue factor expression increases with hypercholes-
terolemia, and it is noteworthy that both of the models in
which hirudin has been effective involve animals with markedly
elevated cholesterol levels. Fourth, the effect of inhibition of
different levels of the coagulation cascade on restenosis can be
studied in this model. Both Abendschein et al. (3) and
Sarembock and colleagues (1,4) have begun this effort by
examining the effects of thrombin inhibition or factor Xa
inhibition. Jang et al. (6), utilizing the cholesterol-fed rabbit
model, found that lower doses of hirudin or rTAP than those
used by Sarembock et al. (1) or Ragosta et al. (4) did not limit
histologic restenosis, but that inhibition of early initiators of
the extrinsic pathway by DEGR-VIIa (which blocks factor
VIIa binding to tissue factor) or tissue factor pathway inhibitor
reduced restenosis. Thus, it may turn out that thrombin is not
the only coagulation protein that mediates intimal growth and
that inhibition of more proximal steps within the extrinsic
coagulation pathway may have pronounced effects.
Finally, a very important question that needs to be ad-
dressed is the role that thrombin receptor blockade may have
on restenosis. Thrombin has a multitude of effects both as a
serine protease and also as mediated through the thrombin
receptor. An agent that blocked the thrombin receptor would
enable the relative contributions of these differing effects to be
examined. Additionally, recent data (7) suggested that the
thrombin receptor may mediate smooth muscle cell growth
independent of activation by thrombin, raising the possibility
that thrombin receptor blockade may have effects more pro-
found than thrombin inhibition. Thus, despite the results of the
HELVETICA trial, it is premature to conclude that thrombin
or the thrombin receptor does not play a role in restenosis
after coronary angioplasty in humans. The fact that we have
not yet shown that thrombin inhibition limits restenosis may
relate more to our inability to safely control this powerful
pathway than to the lack of an important role for thrombin in
the vascular response to injury.
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